Summary: Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α- 18 F-Fluoro-17β-Fluoroestradiol
Journal of Nuclear Medicine · 2023-03 · 64 (3) · 351-354
DOI: 10.2967/jnumed.123.265420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 02.03.2023. Verfasst von Gary A Ulaner und 11 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, California; gary.ulaner@hoag.org. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptors, Estrogen. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
PET imaging with 16α-18F-fluoro-17β-fluoroestradiol (18F-FES), a radiolabeled form of estradiol, allows whole-body, noninvasive evaluation of estrogen receptor (ER). 18F-FES is approved by the U.S. Food and Drug Administration as a diagnostic agent "for the detection of ER-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer." The Society of Nuclear Medicine and Molecular Imaging (SNMMI) convened an expert work group to comprehensively review the published literature for 18F-FES PET in patients with ER-positive breast cancer and to establish appropriate use criteria (AUC). The findings and discussions of the SNMMI 18F-FES work group, including example clinical scenarios, were published in full in 2022 and are available at https://www.snmmi.org/auc Of the clinical scenarios evaluated, the work group concluded that the most appropriate uses of 18F-FES PET are to assess ER functionality when endocrine therapy is considered either at initial diagnosis of metastatic breast cancer or after progression of disease on endocrine therapy, the ER status of lesions that are difficult or dangerous to biopsy, and the ER status of lesions when other tests are inconclusive. These AUC are intended to enable appropriate clinical use of 18F-FES PET, more efficient approval of FES use by payers, and promotion of investigation into areas requiring further research. This summary includes the rationale, methodology, and main findings of the work group and refers the reader to the complete AUC document.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, California; gary.ulaner@hoag.org.
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin.
- Department of Medical Oncology, University of Washington, Seattle, Washington.
- Department of Nuclear Medicine, University of Washington, Seattle, Washington.
Zitieren
APA
Ulaner, G. A., Mankoff, D. A., Clark, A. S., Fowler, A. M., Linden, H. M., Peterson, L. M., Dehdashti, F., Kurland, B. F., Mortimer, J., Mouabbi, J., Moon, D. H., & de Vries, E. G. E. (2023). Summary: Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α- 18 F-Fluoro-17β-Fluoroestradiol. Journal of Nuclear Medicine, 64(3), 351-354. https://doi.org/10.2967/jnumed.123.265420
Vancouver
Ulaner GA, Mankoff DA, Clark AS, Fowler AM, Linden HM, Peterson LM, et al. Summary: Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α- 18 F-Fluoro-17β-Fluoroestradiol. Journal of Nuclear Medicine. 2023;64(3):351-354. doi:10.2967/jnumed.123.265420
BibTeX
@article{Ulaner2023,
author = {Ulaner, Gary A and Mankoff, David A and Clark, Amy S and Fowler, Amy M and Linden, Hannah M and Peterson, Lanell M and Dehdashti, Farrokh and Kurland, Brenda F and Mortimer, Joanne and Mouabbi, Jason and Moon, Dae Hyuk and de Vries, Elisabeth G E},
title = {Summary: Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α- 18 F-Fluoro-17β-Fluoroestradiol},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {3},
pages = {351--354},
doi = {10.2967/jnumed.123.265420}
}
EUVIMED